Home / Health / New Obesity Pill Shows Promise, No Liver Harm
New Obesity Pill Shows Promise, No Liver Harm
6 Jun
Summary
- Experimental obesity pill aleniglipron showed no signs of liver injury.
- Patients on the oral drug continued to lose weight in trials.
- The drug's late-stage program is set to begin in Q3 2026.
Structure Therapeutics reported that its experimental oral obesity pill, aleniglipron, did not exhibit any indications of drug-induced liver injury. Participants in the trial consistently lost weight, with some continuing to do so even on reduced dosages.
Presentations at the American Diabetes Association meeting and publication in a medical journal detailed these findings. Aleniglipron is being developed as a potential rival to popular injectable treatments like Eli Lilly's Foundayo and Novo Nordisk's Wegovy.
In a mid-stage trial, patients on a 180 mg dose of aleniglipron lost up to 39 lbs after 44 weeks. Further analysis of an open-label extension showed sustained weight loss in participants continuing the drug, with no observed weight-loss plateau.
The company indicated improved tolerability at a lower 2.5 mg starting dose. These results are informing the design of the late-stage program, slated to commence in the third quarter of 2026. Gastrointestinal issues like nausea and diarrhea were the most common side effects.
